Related Experiment Video

Updated: Jun 13, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics

Scott E Woodman1, Michael A Davies

  • 1Departments of Melanoma Medical Oncology and Systems Biology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA. swoodman@mdanderson.org

Biochemical Pharmacology
|May 12, 2010
PubMed

Insights

Advanced melanoma treatment remains challenging. However, targeting KIT mutations, common in specific melanoma subtypes, shows promise with tyrosine kinase inhibitors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Dermatology

Background:

  • Advanced melanoma has poor prognoses despite various treatments.
  • Melanoma is molecularly diverse, with subtypes linked to primary tumor location.
  • KIT mutations are prevalent in acral lentiginous, mucosal, and chronic sun-damaged melanomas.

Purpose of the Study:

  • To review the role of KIT in melanocyte development.
  • To summarize current knowledge of KIT genetic alterations in melanoma.
  • To discuss the clinical application of targeting KIT in melanoma treatment.

Main Methods:

  • Literature review of studies on KIT in melanoma.
  • Analysis of genetic aberrations in melanoma subtypes.
  • Examination of clinical trial data for KIT-targeted therapies.

Main Results:

  • KIT mutations are specific to certain melanoma subtypes.
  • Targeting mutant KIT with tyrosine kinase inhibitors shows efficacy.
  • KIT plays a role in melanocyte maturation.

Conclusions:

  • Melanoma subtypes exhibit distinct molecular profiles.
  • KIT genetic aberrations are actionable targets in specific melanomas.
  • Tyrosine kinase inhibitors represent a promising therapeutic strategy for KIT-mutant melanoma.

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...